Division of Rheumatology, First Affiliated Hospital, Inner Mongolia Medical University, Hohhot, People's Republic of China.
Division of Rheumatology, Allergy and Immunology, Stony Brook University, Stony Brook, NY, 11794, USA.
Clin Rheumatol. 2018 Aug;37(8):2021-2026. doi: 10.1007/s10067-018-4178-z. Epub 2018 Jun 17.
Adult-onset Still's disease (AOSD) represents a systemic autoinflammatory disease (SAID), and its diagnostic criteria are clinical without genetic testing. Given shared manifestations between AOSD and hereditary SAIDs, molecular analysis may help differentiate these diseases. A PubMed literature search was conducted using key words "adult-onset Still's disease," "autoinflammatory disease," and "genetic mutation" between 1970 and February 2018. Articles on genetic mutations in the genes MEFV, TNFRSF1A, mevalonate kinase, or NOD2 for hereditary SAIDs in AOSD/systemic onset juvenile idiopathic arthritis (SJIA) patients were reviewed and analyzed. Five case series studies consisting of a total of 162 of both adult and pediatric patients were included. All patients fulfilled the Yamaguchi criteria for AOSD or the diagnostic criteria for SJIA. The results showed that 31.4% (51/162) of patients were identified to carry at least one genetic variant for periodic fever syndromes. In addition, four patients with the diagnosis of SJIA in other reports were confirmed to have FMF or TRAPS with molecular testing. These data together suggest that some patients who satisfy the clinical diagnostic criteria for AOSD/SOJIA could well be diagnosed with other SAIDs; genetic testing, particularly for those with atypical presentation can be supplementary to the accurate disease diagnosis by excluding other autoinflammatory diseases. AOSD is a diagnosis of exclusion and shares common manifestations with other SAIDs. The currently employed clinical criteria for AOSD can cause misdiagnosis. An updated set of classification criteria to integrate the molecular genetic analysis to exclude other autoinflammatory diseases is warranted.
成人Still 病(AOSD)是一种系统性自身炎症性疾病(SAID),其诊断标准是临床标准,不进行基因检测。鉴于 AOSD 与遗传性 SAIDs 之间存在共同表现,分子分析可能有助于区分这些疾病。使用关键词“成人Still 病”、“自身炎症性疾病”和“基因突变”,对 1970 年至 2018 年 2 月的 PubMed 文献进行了检索。综述了 AOSD/全身型幼年特发性关节炎(SJIA)患者中 MEFV、TNFRSF1A、甲羟戊酸激酶或 NOD2 基因遗传突变的相关文章,并进行了分析。共纳入了 5 项包含总计 162 例成人和儿童患者的病例系列研究。所有患者均符合 AOSD 的 Yamaguchi 标准或 SJIA 的诊断标准。结果显示,51/162(31.4%)例患者至少携带一种周期性发热综合征的遗传变异。此外,其他报道中被诊断为 SJIA 的 4 例患者经分子检测证实患有 FMF 或 TRAPS。这些数据表明,一些符合 AOSD/SOJIA 临床诊断标准的患者可能被诊断为其他 SAIDs;遗传检测,尤其是对那些表现不典型的患者,通过排除其他自身炎症性疾病,可以辅助准确的疾病诊断。AOSD 是一种排除性诊断,与其他 SAIDs 具有共同表现。目前用于 AOSD 的临床标准可能导致误诊。有必要制定一套新的分类标准,将分子遗传学分析整合进来,以排除其他自身炎症性疾病。